JMP Securities Reiterates a Buy Rating on Medgenics

By Ryan Adsit

In a report released today, Michael King from JMP Securities reiterated a Buy rating on Medgenics (NYSE: MDGN). The company’s shares opened today at $4.50.

According to, King is ranked 0 out of 5 stars with an average return of -13.7% and a 25.3% success rate. King covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Syndax Pharmaceuticals Inc, and Karyopharm Therapeutics.

Medgenics has an analyst consensus of Moderate Buy.

The company has a one year high of $5.17 and a one year low of $4. Currently, Medgenics has an average volume of 121.6K.

Medgenics, Inc. is a medical technology company, which develops protein therapeutics medical therapies. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The Company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.